Have a feature idea you'd love to see implemented?
Let us know!
PRAX Praxis Precision Medicines Inc
Price (delayed)
$65.84
Market cap
$1.23B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.22
Enterprise value
$1.06B
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights
Highlights
PRAX's EPS has surged by 72% year-on-year
The debt has declined by 40% year-on-year and by 15% since the previous quarter
The quick ratio has soared by 80% year-on-year but it has declined by 36% since the previous quarter
The net income has contracted by 22% from the previous quarter and by 10% YoY
The gross profit has declined by 17% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of PRAX
Market
Valuations
Earnings
Shares outstanding
18.64M
Market cap
$1.23B
Enterprise value
$1.06B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.06
Price to sales (P/S)
774.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
660.51
Revenue
$1.61M
Gross profit
$1.61M
Net income
-$151.02M
EBIT
-$151.02M
EBITDA
-$149.69M
Free cash flow
-$99.55M
Per share
Balance sheet
Liquidity
EPS
-$9.22
EPS diluted
-$9.22
Free cash flow per share
-$5.27
Book value per share
$21.55
Revenue per share
$0.08
TBVPS
$22.04
Total assets
$416.26M
Total liabilities
$33.59M
Debt
$1.66M
Equity
$382.67M
Working capital
$327.19M
Debt to equity
0
Current ratio
10.96
Quick ratio
10.86
Net debt/EBITDA
1.12
Margins
Efficiency
Dividend
EBITDA margin
-9,326.4%
Gross margin
100%
Net margin
-9,409.2%
Operating margin
-10,219%
Return on assets
-50.5%
Return on equity
-54.9%
Return on invested capital
-106.2%
Return on capital employed
-39.4%
Return on sales
-9,409.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRAX stock price
How has the Praxis Precision Medicines stock price performed over time
Intraday
2.84%
1 week
-15.07%
1 month
-6.18%
1 year
51.81%
YTD
-14.45%
QTD
-14.45%
Financial performance
How have Praxis Precision Medicines's revenue and profit performed over time
Revenue
$1.61M
Gross profit
$1.61M
Operating income
-$164.02M
Net income
-$151.02M
Gross margin
100%
Net margin
-9,409.2%
PRAX's operating margin is down by 41% year-on-year and by 36% since the previous quarter
The net margin has declined by 35% since the previous quarter and by 32% year-on-year
The operating income has declined by 24% since the previous quarter and by 17% year-on-year
The net income has contracted by 22% from the previous quarter and by 10% YoY
Growth
What is Praxis Precision Medicines's growth rate over time
Valuation
What is Praxis Precision Medicines stock price valuation
P/E
N/A
P/B
3.06
P/S
774.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
660.51
PRAX's EPS has surged by 72% year-on-year
PRAX's P/B is 22% above its 5-year quarterly average of 2.5 and 13% above its last 4 quarters average of 2.7
PRAX's equity is down by 9% from the previous quarter
The price to sales (P/S) is 98% more than the last 4 quarters average of 390.8
The revenue has declined by 17% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Praxis Precision Medicines business performance
Praxis Precision Medicines's ROE has soared by 67% YoY and by 11% from the previous quarter
Praxis Precision Medicines's ROA has soared by 58% YoY and by 10% from the previous quarter
PRAX's return on sales is down by 35% since the previous quarter and by 32% year-on-year
The company's return on invested capital rose by 26% QoQ
Dividends
What is PRAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRAX.
Financial health
How did Praxis Precision Medicines financials performed over time
The quick ratio has soared by 80% year-on-year but it has declined by 36% since the previous quarter
PRAX's current ratio has surged by 78% year-on-year but it is down by 37% since the previous quarter
The debt is 100% smaller than the equity
The debt to equity has dropped by 100% year-on-year
The debt has declined by 40% year-on-year and by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.